Blosozumab |
| Catalog No.GC66384 |
Blosozumab (LY2541546) est un anticorps anti-sclérostine humaine (SOST). Le blozozumab stimule la formation osseuse et réduit la résorption osseuse. Blosozumab peut être utilisé dans la recherche de l'ostéoporose.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1132758-87-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis[1][2].
Blosozumab (1-100 mg/kg, i.v.) shows effects of hyperostosis in rats[1].
| Animal Model: | Sprague-Dawley rats [2] |
| Dosage: | 1, 10, and 100 mg/kg |
| Administration: | Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study) |
| Result: | Observed the bone anabolic effects. Showed significant bleeding and morbidity at 100 mg/kg. Decreases in the numbers of platelets. Increased number of bone marrow megakaryocytes at 100 mg/kg. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *